Knockdown of VEGFR2 Inhibits Proliferation and Induces Apoptosis in Hemangioma-Derived Endothelial Cells

Angiogenesis is a process of development and growth of new capillary blood vessels from pre-existing vessels. Angiogenic growth factors play important roles in the development and maintenance of some malignancies, of which vascular endothelial growth factor (VEGF)/VEGFR2 interactions are involved in proliferation, migration, and survival of many cancer cells. The aim of this study was to investigate the function of VEGFR2 in human hemangiomas (HAs). Using immunohistochemistry assay, we examined the expression levels of VEGF, VEGFR2, Ki-67, glucose transporter-1 (Glut-1), phosphorylated protein kinase B (p-AKT) and p-ERK in different phases of human HAs. Positive expression of VEGF, VEGFR2, Ki-67, Glut-1, p-AKT and p-ERK was significantly increased in proliferating phase HAs, while decreased in involuting phase HAs (P=0.001; P=0.003). In contrast, cell apoptotic indexes were decreased in proliferating phase HAs, but increased in involuting phase HAs (P<0.01). Furthermore, we used small hairpin RNA (shRNA)-mediated VEGFR2 knockdown in primary HA-derived endothelial cells (HemECs) to understand the role of VEGF/VEGFR2 signaling. Knockdown of VEGFR2 by Lv-shVEGFR2 inhibited cell viability and induced apoptosis in primary HemECs companied with decreased expression of p-AKT, p-ERK, p-p38MAPK and Ki-67 and increased expression of caspase-3 (CAS-3); Overexpression of VEGFR2 promoted cell viability and blocked apoptosis in Lv-VEGFR2-transfected HemECs. Taken together, our findings demonstrate that, increased expression of VEGFR2 is involved in the development of primary HemECs possibly through regulation of the AKT and ERK pathways, suggesting that VEGFR2 may be a potential therapeutic target for HAs.Key words: vascular endothelial growth factor receptor 2, hemangioma, proliferation, apoptosis     

Fibroblasts Derived from Human Pluripotent Stem Cells Activate Angiogenic Responses In Vitro and In Vivo

Human embryonic and induced pluripotent stem cells (hESC/hiPSC) are promising cell sources for the derivation of large numbers of specific cell types for tissue engineering and cell therapy applications. We have describe a directed differentiation protocol that generates fibroblasts from both hESC and hiPSC (EDK/iPDK) that support the repair and regeneration of epithelial tissue in engineered, 3D skin equivalents. In the current study, we analyzed the secretory profiles of EDK and iPDK cells to investigate the production of factors that activate and promote angiogenesis. Analysis of in vitro secretion profiles from EDK and iPDK cells demonstrated the elevated secretion of pro-angiogenic soluble mediators, including VEGF, HGF, IL-8, PDGF-AA, and Ang-1, that stimulated endothelial cell sprouting in a 3D model of angiogenesis in vitro. Phenotypic analysis of EDK and iPDK cells during the course of differentiation from hESCs and iPSCs revealed that both cell types progressively acquired pericyte lineage markers NG2, PDGFRβ, CD105, and CD73 and demonstrated transient induction of pericyte progenitor markers CD31, CD34, and Flk1/VEGFR2. Furthermore, when co-cultured with endothelial cells in 3D fibrin-based constructs, EDK and iPDK cells promoted self-assembly of vascular networks and vascular basement membrane deposition. Finally, transplantation of EDK cells into mice with hindlimb ischemia significantly reduced tissue necrosis and improved blood perfusion, demonstrating the potential of these cells to stimulate angiogenic responses in vivo. These findings demonstrate that stable populations of pericyte-like angiogenic cells can be generated with high efficiency from hESC and hiPSC using a directed differentiation approach. This provides new cell sources and opportunities for vascular tissue engineering and for the development of novel strategies in regenerative medicine.     

干扰PKM2对人白血病细胞增殖和凋亡的影响及潜在机制

目的:探讨糖酵解酶丙酮酸激酶M2型(PKM2)对人白血病细胞体外增殖和凋亡的影响及潜在机制。方法:将靶向PKM2的慢病毒载体转染人K562细胞株(sh PKM2组),同时设立空载体转染组为对照(Vector组)。采用qRT-PCR和Western blot技术分别检测Vector组和sh PKM2组PKM2 mRNA和蛋白的表达以及自噬标志物的变化; CCK-8实验检测细胞体外增殖能力;流式细胞术检测细胞周期和凋亡情况; Western blot检测凋亡相关蛋白Bax、Bcl-2表达水平。结果:在稳定干扰PKM2后,PKM2的mRNA(t=11. 58,P=0. 000 3)和蛋白水平(t=11. 88,P=0. 000 3)均明显降低。与Vector组比较,shPKM2组细胞体外增殖能力显著降低(F=118. 87,P 0. 000 1)。同时,干扰PKM2可使K562细胞周期阻滞在G1期,细胞凋亡率显著增加(t=37. 23,P 0. 000 1);使促凋亡蛋白Bax表达增加(t=15. 36,P=0. 000 1)、抗凋亡蛋白Bcl-2表达降低(t=9. 965,P=0. 000 6)。此外,干扰PKM2可减弱K562细胞自噬水平,表现为LC3Ⅱ降低(t_(LC3Ⅱ)=10. 32,P_(LC3Ⅱ)=0. 000 5),而p62水平增加(t_(p62)=14. 59,P_(p62)=0. 000 1)。还发现自噬诱导剂能逆转shPKM2引起的白血病细胞体外增殖能力减弱(F=96. 32,P 0. 000 1)。结论:以上结果表明干扰PKM2可抑制人白血病K562细胞的体外增殖并促进其凋亡,其机制可能与PKM2介导的自噬活性降低有关,提示PKM2可能作为白血病诊疗的一个潜在靶点。     

Salinomycin Inhibits Proliferation and Induces Apoptosis of Human Hepatocellular Carcinoma Cells In Vitro and In Vivo

The anti-tumor antibiotic salinomycin (Sal) was recently identified as a selective inhibitor of breast cancer stem cells; however, the effect of Sal on hepatocellular carcinoma (HCC) is not clear. This study aimed to determine the anti-tumor efficacy and mechanism of Sal on HCC. HCC cell lines (HepG2, SMMC-7721, and BEL-7402) were treated with Sal. Cell doubling time was determinated by drawing growth curve, cell viability was evaluated using the Cell Counting Kit 8. The fraction of CD133⁺ cell subpopulations was assessed by flow cytometry. We found that Sal inhibits proliferation and decreases PCNA levels as well as the proportion of HCC CD133⁺cell subpopulations in HCC cells. Cell cycle was analyzed using flow cytometry and showed that Sal caused cell cycle arrest of the various HCC cell lines in different phases. Cell apoptosis was evaluated using flow cytometry and Hoechst 33342 staining. Sal induced apoptosis as characterized by an increase in the Bax/Bcl-2 ratio. Several signaling pathways were selected for further mechanistic analyses using real time-PCR and Western blot assays. Compared to control, β-catenin expression is significantly down-regulated upon Sal addition. The Ca²⁺ concentration in HCC cells was examined by flow cytometry and higher Ca²⁺ concentrations were observed in Sal treatment groups. The anti-tumor effect of Sal was further verified in vivo using the hepatoma orthotopic tumor model and the data obtained showed that the size of liver tumors in Sal-treated groups decreased compared to controls. Immunohistochemistry and TUNEL staining also demonstrated that Sal inhibits proliferation and induces apoptosis in vivo. Finally, the role of Sal on in vivo Wnt/β-catenin signaling was evaluated by Western blot and immunohistochemistry. This study demonstrates Sal inhibits proliferation and induces apoptosis of HCC cells in vitro and in vivo and one potential mechanism is inhibition of Wnt/β-catenin signaling via increased intracellular Ca²⁺ levels.     

Effects of 5-Fluorouracil on Morphology,Cell Cycle,Proliferation, Apoptosis,Autophagy and ROS Production in Endothelial Cells and Cardiomyocytes

Antimetabolites are a class of effective anticancer drugs interfering in essential biochemical processes. 5-Fluorouracil (5-FU) and its prodrug Capecitabine are widely used in the treatment of several solid tumors (gastro-intestinal, gynecological, head and neck, breast carcinomas). Therapy with fluoropyrimidines is associated with a wide range of adverse effects, including diarrhea, dehydration, abdominal pain, nausea, stomatitis, and hand-foot syndrome. Among the 5-FU side effects, increasing attention is given to cardiovascular toxicities induced at different levels and intensities. Since the mechanisms related to 5-FU-induced cardiotoxicity are still unclear, we examined the effects of 5-FU on primary cell cultures of human cardiomyocytes and endothelial cells, which represent two key components of the cardiovascular system. We analyzed at the cellular and molecular level 5-FU effects on cell proliferation, cell cycle, survival and induction of apoptosis, in an experimental cardioncology approach. We observed autophagic features at the ultrastructural and molecular levels, in particular in 5-FU exposed cardiomyocytes. Reactive oxygen species (ROS) elevation characterized the endothelial response. These responses were prevented by a ROS scavenger. We found induction of a senescent phenotype on both cell types treated with 5-FU. In vivo, in a xenograft model of colon cancer, we showed that 5-FU treatment induced ultrastructural changes in the endothelium of various organs. Taken together, our data suggest that 5-FU can affect, both at the cellular and molecular levels, two key cell types of the cardiovascular system, potentially explaining some manifestations of 5-FU-induced cardiovascular toxicity.     

nAChRs Mediate Human Embryonic Stem Cell-Derived Endothelial Cells: Proliferation,Apoptosis, and Angiogenesis

Background

Many patients with ischemic heart disease have cardiovascular risk factors such as cigarette smoking. We tested the effect of nicotine (a key component of cigarette smoking) on the therapeutic effects of human embryonic stem cell-derived endothelial cells (hESC-ECs).

Methods and Results

To induce endothelial cell differentiation, undifferentiated hESCs (H9 line) underwent 4-day floating EB formation and 8-day outgrowth differentiation in EGM-2 media. After 12 days, CD31⁺ cells (13.7±2.5%) were sorted by FACScan and maintained in EGM-2 media for further differentiation. After isolation, these hESC-ECs expressed endothelial specific markers such as vWF (96.3±1.4%), CD31 (97.2±2.5%), and VE-cadherin (93.7±2.8%), form vascular-like channels, and incorporated DiI-labeled acetylated low-density lipoprotein (DiI-Ac-LDL). Afterward, 5×10⁶ hESC-ECs treated for 24 hours with nicotine (10⁻⁸ M) or PBS (as control) were injected into the hearts of mice undergoing LAD ligation followed by administration for two weeks of vehicle or nicotine (100 µg/ml) in the drinking water. Surprisingly, bioluminescence imaging (BLI) showed significant improvement in the survival of transplanted hESC-ECs in the nicotine treated group at 6 weeks. Postmortem analysis confirmed increased presence of small capillaries in the infarcted zones. Finally, in vitro mechanistic analysis suggests activation of the MAPK and Akt pathways following activation of nicotinic acetylcholine receptors (nAChRs).

Conclusions

This study shows for the first time that short-term systemic administrations of low dose nicotine can improve the survival of transplanted hESC-ECs, and enhance their angiogenic effects in vivo. Furthermore, activation of nAChRs has anti-apoptotic, angiogenic, and proliferative effects through MAPK and Akt signaling pathways.     

Inhibiting Effects of a Cyclic Peptide CNGRC on Proliferation and Migration of Tumor Cells In Vitro

The cyclic peptide Cys-Asn-Gly-Arg-Cys (CNGRC) has previously been demonstrated as a tumor vasculature-homing peptide, which can specifically bind to CD13/aminopeptidase N in vivo. However, the effect of the peptide (CNGRC) binding to tumor cells in vitro has not yet been reported. In this study, CNGRC and an irrelevant linear control peptide (SVSVG) were employed to investigate the specific binding properties and other cellular influences in vitro. Immunofluorescence revealed that the peptide CNGRC demonstrated high specificities to the cells MDA-MB-435S, A549, MDA-MB-231, SK-OV-3 and EA.hy926, respectively. The cell viability assay indicated that CNGRC inhibited the proliferation of tumor cells at 24, 48 and 72 h. Furthermore, the peptide efficiently inhibited the migration of tumor cells, but promoted the migration of the human umbilical vein cell line. These results demonstrate that the synthetic peptide CNGRC can bind to the tumor cells without aminopeptidase N (CD13) expressed on the membranes. Therefore, it is supposed that the mechanism of the peptide binding to tumor cells in vitro may be different from that in vivo.     

RY10-4 Inhibits the Proliferation of Human Hepatocellular Cancer HepG2 Cells by Inducing Apoptosis In Vitro and In Vivo

This study aimed to investigate the anti-tumor activity of RY10-4, a small molecular that was designed and synthesized based on the structure of protoapigenone. A previous screening study showed that RY10-4 possessed anti-proliferative effects against HepG2 human hepatocellular carcinoma cells. However, the full range of RY10-4 anti-cancer effects on liver tumors and the underlying mechanisms have not been identified. Herein, employing flow cytometry, and Western blot analysis, we demonstrate that RY10-4 can induce cell cycle arrest, intracellular reactive oxygen species (ROS) production and apoptosis in HepG2 cells. In HepG2 cell xenograft tumor model, RY10-4 significantly inhibited the growth of tumors and induced apoptosis in tumor cells, with little side effects. Moreover, RY10-4 caused the suppression of STAT3 activation, which may be involved the apoptosis induction. In addition, RY10-4 inhibited the proliferation of Hep3B and HuH-7 human hepatocellular carcinoma cells in a concentration-dependent manner. Taken together, our results suggest that RY10-4 has a great potential to develop as chemotherapeutic agent for liver cancer.     

Functional Effects of FGF-13 on Human Lung Fibroblasts,Dermal Microvascular Endothelial Cells,and Aortic Smooth Muscle Cells

We studied the effects of FGF-13 and FGF-2 on human lung fibroblasts, dermal microvascular endothelial cells, and aortic smooth muscle cells. FGF-13 induced cell growth of lung fibroblasts and aortic smooth muscle cells but had no effect on dermal vascular endothelial cells. FGF-2 induced cell growth in all the three cell types. FGF-13 and FGF-2 had little effect on IL-6 production by lung fibroblasts and aortic smooth muscle cells and substantially enhanced that induced by IL-1α. In contrast, FGF-13 and FGF-2 had little effect on IL-6 production by dermal vascular endothelial cells, either alone or in synergy with IL-1α.     

The Reversal Effects of 3-Bromopyruvate on Multidrug Resistance In Vitro and In Vivo Derived from Human Breast MCF-7/ADR Cells

Purpose

P-glycoprotein mediated efflux is one of the main mechanisms for multidrug resistance in cancers, and 3-Bromopyruvate acts as a promising multidrug resistance reversal compound in our study. To test the ability of 3-Bromopyruvate to overcome P-glycoprotein-mediated multidrug resistance and to explore its mechanisms of multidrug resistance reversal in MCF-7/ADR cells, we evaluate the in vitro and in vivo modulatory activity of this compound.

Methods

The in vitro and in vivo activity was determined using the MTT assay and human breast cancer xenograft models. The gene and protein expression of P-glycoprotein were determined using real-time polymerase chain reaction and the Western blotting technique, respectively. ABCB-1 bioactivity was tested by fluorescence microscopy, multi-mode microplate reader, and flow cytometry. The intracellular levels of ATP, HK-II, and ATPase activity were based on an assay kit according to the manufacturer’s instructions.

Results

3-Bromopyruvate treatment led to marked decreases in the IC₅₀ values of selected chemotherapeutic drugs [e.g., doxorubicin (283 folds), paclitaxel (85 folds), daunorubicin (201 folds), and epirubicin (171 folds)] in MCF-7/ADR cells. 3-Bromopyruvate was found also to potentiate significantly the antitumor activity of epirubicin against MCF-7/ADR xenografts. The intracellular level of ATP decreased 44%, 46% in the presence of 12.5.25 µM 3-Bromopyruvate, whereas the accumulation of rhodamine 123 and epirubicin (two typical P-glycoprotein substrates) in cells was significantly increased. Furthermore, we found that the mRNA and the total protein level of P-glycoprotein were slightly altered by 3-Bromopyruvate. Moreover, the ATPase activity was significantly inhibited when 3-Bromopyruvate was applied.

Conclusion

We demonstrated that 3-Bromopyruvate can reverse P-glycoprotein-mediated efflux in MCF-7/ADR cells. Multidrug resistance reversal by 3-Bromopyruvate occurred through at least three approaches, namely, a decrease in the intracellular level of ATP and HK-II bioactivity, the inhibition of ATPase activity, and the slight decrease in P-glycoprotein expression in MCF-7/ADR cells.     

藏红花素对白血病患儿骨髓树突状细胞体外增殖作用的影响

目的:探讨藏红花素(crocin)对白血病患儿骨髓树突状细胞体外增殖作用的影响。方法:采用Ficoll-Hypaque法分离急性白血病患者骨髓液单个核细胞,将本实验分为六组。培养至第9天,在倒置显微镜下观察各组细胞形态,对各组细胞进行计数,并行瑞氏-姬姆萨染液染色,在油镜下观察典型树突状细胞的形态,应用流式细胞仪检测各组细胞免疫表型。结果:结果表明,实验各组均得到一定数量典型的DC,对照组中未见,实验各组细胞数目明显高于对照组,差异有显著统计学意义(P<0.01)。在加入细胞因子的各组中,以E组即加入藏红花素1.25mg/ml组细胞数最高,而C组细胞数与D组细胞数比较无显著差异(P>0.05)。培养至第9天,流式细胞仪免疫分析显示C、D、E、F各组CD1a+、CD83+、HLA-DR+细胞比例明显高于A、B两组(P<0.01),差异有显著统计学意义,A、B两组之间比较差异无统计学意义(P>0.05)。D、F组与C组比较,差异无统计学意义(P>0.05)。E组与C、D、F组比较,差异有统计学意义(P<0.05)。结论:藏红花素能促进树突状细胞增殖,其促进树突状细胞增殖的能力明显弱于细胞因子的联合作用。藏红花素协同细胞因子促进树突状细胞的成熟具有浓度依赖性,在藏红花素浓度为1.25mg/ml时作用最强,而浓度过高或过低时均未表现出明显的促进作用。     

藏红花素对白血病患儿骨髓树突状细胞体外增殖作用的影响

目的：探讨藏红花素（crocin）对白血病患儿骨髓树突状细胞体外增殖作用的影响。方法：采用Ficoll-Hypaque法分离急性白血病患者骨髓液单个核细胞,将本实验分为六组。培养至第9天,在倒置显微镜下观察各组细胞形态,对各组细胞进行计数,并行瑞氏-姬姆萨染液染色,在油镜下观察典型树突状细胞的形态,应用流式细胞仪检测各组细胞免疫表型。结果：结果表明,实验各组均得到一定数量典型的DC,对照组中未见,实验各组细胞数目明显高于对照组,差异有显著统计学意义（P〈0.01）。在加入细胞因子的各组中,以E组即加入藏红花素1.25mg/ml组细胞数最高,而C组细胞数与D组细胞数比较无显著差异（P〉0.05）。培养至第9天,流式细胞仪免疫分析显示C、D、E、F各组CD1a＋、CD83＋、HLA-DR＋细胞比例明显高于A、B两组（P〈0.01）,差异有显著统计学意义,A、B两组之间比较差异无统计学意义（P〉0.05）。D、F组与C组比较,差异无统计学意义（P〉0.05）。E组与C、D、F组比较,差异有统计学意义（P〈0.05）。结论：藏红花素能促进树突状细胞增殖,其促进树突状细胞增殖的能力明显弱于细胞因子的联合作用。藏红花素协同细胞因子促进树突状细胞的成熟具有浓度依赖性,在藏红花素浓度为1.25mg/ml时作用最强,而浓度过高或过低时均未表现出明显的促进作用。     

Aciculatin Induces p53-Dependent Apoptosis via MDM2 Depletion in Human Cancer Cells In Vitro and In Vivo

Aciculatin, a natural compound extracted from the medicinal herb Chrysopogon aciculatus, shows potent anti-cancer potency. This study is the first to prove that aciculatin induces cell death in human cancer cells and HCT116 mouse xenografts due to G1 arrest and subsequent apoptosis. The primary reason for cell cycle arrest and cell death was p53 accumulation followed by increased p21 level, dephosphorylation of Rb protein, PUMA expression, and induction of apoptotic signals such as cleavage of caspase-9, caspase-3, and PARP. We demonstrated that p53 allele-null (-/-) (p53-KO) HCT116 cells were more resistant to aciculatin than cells with wild-type p53 (+/+). The same result was achieved by knocking down p53 with siRNA in p53 wild-type cells, indicating that p53 plays a crucial role in aciculatin-induced apoptosis. Although DNA damage is the most common event leading to p53 activation, we found only weak evidence of DNA damage after aciculatin treatment. Interestingly, the aciculatin-induced downregulation of MDM2, an important negative regulator of p53, contributed to p53 accumulation. The anti-cancer activity and importance of p53 after aciculatin treatment were also confirmed in the HCT116 xenograft models. Collectively, these results indicate that aciculatin treatment induces cell cycle arrest and apoptosis via inhibition of MDM2 expression, thereby inducing p53 accumulation without significant DNA damage and genome toxicity.     

人骨髓基质细胞体外分离及定向培养内皮细胞

用Ficoll(比重1.077 g/ml)从正常成人骨髓中分离骨髓基质细胞(BMSCs),DMEM-HG 培养基内含20?S、GM-CSF(100 u/ml)、VEGF(10 ng/ml)、FGF(5 ng/ml)、L-谷氨酰胺(2mmol/ L)、肝素(90 u/ml),以及抗生素液进行定向培养和扩增其中的内皮细胞(ECs),Ⅷ因子相关抗原的免疫组化法和透射电镜观察(TEM)鉴定其细胞的性质。结果5.0×105个BMSCs在体外经定向ECs 培养和扩增8代后,获得了6.0×109个ECs,扩增了约1.2×104倍。70%-80%的细胞对Ⅷ因子相关抗原免疫组化呈阳性反应;光镜下细胞呈典型的“鹅卵石”样;TEM下可观察到胞浆内有Weible- palade小体,证实为内皮细胞。实验表明,BMSCs在体外分离和定向培养的ECs,经扩增后可能是心血管组织工程所需种子细胞的又一个重要来源。     

TFPI-2对人肝癌细胞生长增殖、凋亡及AFP合成的影响

目的: 探讨TFPI-2基因对人肝癌细胞Hep3B生长增殖、凋亡及甲胎蛋白AFP表达的影响。 方法: 将重组质粒PCDNA3.1-TFPI-2转染Hep3B细胞并经G418稳定筛选后,RT-PCR和Western blot检测转染前后TFPI-2 mRNA和蛋白表达水平,采用CCK-8法、生长曲线观察TFPI-2对人肝癌细胞Hep3B生长增殖的影响,通过平板克隆形成实验观察单个细胞的增殖能力,RT-PCR检测AFP mRNA的表达,并用电化学发光法测定培养上清液中甲胎蛋白AFP含量,流式细胞仪检测细胞早晚期凋亡情况。 结果: 转染成功的Hep3B细胞检测到TFPI-2 mRNA和蛋白的表达;与转染空载体及未转染的细胞相比,转染TFPI-2的细胞生长增殖能力明显减弱;AFP mRNA表达抑制率为16.51%,AFP蛋白分泌明显低于对照组(P<0.01);流式细胞术检测转染TFPI-2的Hep3B细胞早期凋亡率明显增加(24.03%±7.28% vs 8.77%±3.66%)。 结论: TFPI-2表达可显著抑制肝癌细胞生长和AFP的表达,同时还能诱导细胞早期凋亡。为进一步探讨靶向TFPI-2的肝癌基因治疗提供了实验依据。     

Soluble LRIG2 Ectodomain Is Released from Glioblastoma Cells and Promotes the Proliferation and Inhibits the Apoptosis of Glioblastoma Cells In Vitro and In Vivo in a Similar Manner to the Full-Length LRIG2

The human leucine-rich repeats and immunoglobulin-like domains (LRIG) gene family contains LRIG1, 2 and 3, encoding integral membrane proteins with an ectodomain, a transmembrane domain and a cytoplasmic tail. LRIG1 negatively regulates multiple receptor tyrosine kinases signaling including the epidermal growth factor receptor (EGFR) and is a proposed tumor suppressor. The soluble LRIG1 ectodomain is demonstrated to be shed naturally and inhibit the progression of glioma. However, little is known regarding the functions of LRIG2. In oligodendroglioma, LRIG2 expression is associated with poor survival, suggesting that LRIG2 might have different functions compared with LRIG1. Since soluble LRIG1 ectodomain has a similar function to the full-length LRIG1, we hypothesize that the different roles exerted by LRIG2 and LRIG1 result from the difference of their ectodomains. Here, we addressed the functions of LRIG2 and LRIG2 ectodomain in the proliferation and apoptosis of glioma and the possible underlying mechanisms. Firstly, we found that LRIG2 expression levels positively correlated with the grade of glioma. Further, we demonstrated for the first time that soluble LRIG2 ectodomain was capable of being released from glioblastoma cells and exerted a pro-proliferative effect. Overexpression of LRIG2 ectodomain promoted the proliferation and inhibited the apoptosis of glioblastoma cells in vitro and in vivo in a similar manner to the full-length LRIG2. Both full-length LRIG2 and LRIG2 ectodomain were found to physically interact with EGFR, enhance the activation of EGFR and its downstream PI3 K/Akt pathway. To our knowledge, this is the first report demonstrating that soluble LRIG2 ectodomain is capable of being released from glioblastoma cells and exerts a similar role to the full-length LRIG2 in the regulation of EGFR signaling in the progression of glioblastoma. LRIG2 ectodomain, with potent pro-tumor effects, holds promise for providing a new therapeutic target for the treatment of glioblastoma.     

Adult Stromal Cells Derived from Human Adipose Tissue Provoke Pancreatic Cancer Cell Death both In Vitro and In Vivo

Background

Normal tissue homeostasis is maintained by dynamic interactions between epithelial cells and their microenvironment. Disrupting this homeostasis can induce aberrant cell proliferation, adhesion, function and migration that might promote malignant behavior. Indeed, aberrant stromal-epithelial interactions contribute to pancreatic ductal adenocarcinoma (PDAC) spread and metastasis, and this raises the possibility that novel stroma-targeted therapies represent additional approaches for combating this malignant disease. The aim of the present study was to determine the effect of human stromal cells derived from adipose tissue (ADSC) on pancreatic tumor cell proliferation.

Principal Findings

Co-culturing pancreatic tumor cells with ADSC and ADSC-conditioned medium sampled from different donors inhibited cancer cell viability and proliferation. ADSC-mediated inhibitory effect was further extended to other epithelial cancer-derived cell lines (liver, colon, prostate). ADSC conditioned medium induced cancer cell necrosis following G1-phase arrest, without evidence of apoptosis. In vivo, a single intra-tumoral injection of ADSC in a model of pancreatic adenocarcinoma induced a strong and long-lasting inhibition of tumor growth.

Conclusion

These data indicate that ADSC strongly inhibit PDAC proliferation, both in vitro and in vivo and induce tumor cell death by altering cell cycle progression. Therefore, ADSC may constitute a potential cell-based therapeutic alternative for the treatment of PDAC for which no effective cure is available.